Detalhe da pesquisa
1.
Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex.
J Biol Chem
; 297(4): 101102, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34419446
2.
An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Mol Ther
; 28(3): 889-900, 2020 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31981494
3.
High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region.
J Immunol
; 190(4): 1481-90, 2013 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23303672
4.
Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9.
J Biol Chem
; 287(14): 11090-7, 2012 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22294692
5.
Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis.
Anal Biochem
; 411(1): 139-51, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21168382
6.
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
J Immunother Cancer
; 9(10)2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34599020
7.
Direct control of CAR T cells through small molecule-regulated antibodies.
Nat Commun
; 12(1): 710, 2021 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33514714
8.
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.
MAbs
; 13(1): 1871171, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33557687
9.
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Cancer Immunol Res
; 9(10): 1141-1157, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376502
10.
A global benchmark study using affinity-based biosensors.
Anal Biochem
; 386(2): 194-216, 2009 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19133223
11.
Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.
Cell Rep
; 27(11): 3117-3123.e5, 2019 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31189099
12.
Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Sci Rep
; 9(1): 16735, 2019 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31700121
13.
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.
Sci Rep
; 9(1): 2443, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30792442
14.
Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Sci Rep
; 9(1): 8420, 2019 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31182754
15.
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Mol Cancer Ther
; 18(11): 2008-2020, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31434693
16.
RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models.
Oncotarget
; 9(71): 33446-33458, 2018 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323890
17.
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Nat Commun
; 9(1): 4679, 2018 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30410017
18.
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.
MAbs
; 10(2): 256-268, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29227213
19.
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
J Hematol Oncol
; 10(1): 112, 2017 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526063
20.
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
Blood Adv
; 1(15): 1088-1100, 2017 Jun 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296751